Standard BioTools Q1 revenue $21.1M, up 5% YoY; operating loss cut 54%

STANDARD BIOTOOLS INC.

2026-Q1 EPS reported $0.33 revenue$21,146,000

Net loss from continuing ops $14.6M vs $23.4M YoY; adjusted EBITDA loss $3.1M, 78% improvement.
Revenue $21.1M (+5% YoY); consumables up 35% to $11.0M, instruments down 33% to $4.5M.
Cash & investments $524M at quarter end, plus $25M earnout received post-Q1; total ~$550M.
Full-year 2026 revenue outlook unchanged at $80M-$85M; path to positive adjusted EBITDA exiting 2026.
Operating expenses down 37% to $23.8M, helped by restructuring; non-GAAP gross margin 57.7%.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STANDARD BIOTOOLS INC. reported the quarter ended March 31, 2026 results: revenue $21.1 million, net income $14.6 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $21.1 million
Net income: $14.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: • First quarter 2026 revenue of $21.1 million • 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026 • $524 million in cash &

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-206395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.